ADELMIDROL FOR USE IN DISEASES CHARACTERIZED BY INSUFFICIENT ACTION OF PPAR-γ RECEPTOR

摘要

PROBLEM TO BE SOLVED: To provide a pharmaceutical composition containing adelmidrol.SOLUTION: Disclosed is use of adelmidrol for the treatment of diseases characterized by the insufficient particular action of PPAR-γ receptor, more specifically, for the treatment of articular cartilage disease by mechanical, toxicity, iatrogenesis or degenerative causes, or of articular cartilage disease associated with inflammation events mainly related to organs and tissues not belonging to osteoarticular systems; of articular cartilage fibrogenesis; of chronic inflammatory bowel disease (IBD), for example, Crohn's disease and ulcerative colitis; of irritable bowel syndrome (IBS); of connective tissue, particularly skin and lung abnormal fibrosis, for example, systemic sclerosis; of eye diseases characterized by angiogenesis, fibrosis, inflammation, and oxidative stress, in humans and animals, the adelmidrol being symmetrical diethanolamide of azelaic acid and being represented by the following formula.SELECTED DRAWING: None